PET scan could predict best next drug for advanced breast cancer
NCT ID NCT06595563
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study is for people with advanced HER2-positive breast cancer whose disease has worsened after a drug called T-DXd. Researchers will use a special PET scan to see if the cancer still has HER2 on its surface. If the scan is positive, participants get a different drug called T-DM1; if negative, they receive standard care. The goal is to see if this scan can help doctors choose the most effective next treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Jules Bordet
RECRUITINGAnderlecht, Brussels Capital, 1070, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.